Developer docs
API playgroundTry for free, no card

Search company profiles

NILO Therapeutics

Full company profile

uuid00000kh

Namestring
NILO Therapeutics
Legal namestring
Nilo Therapeutics
Websiteurl
nilotx.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

NILO Therapeutics is a New York City-based, preclinical-stage biotechnology company developing a new class of medicines that modulate systemic inflammation by targeting master regulator brain-body circuits. Its core asset is the Neural Circuit Immunomodulation Platform, a therapeutic approach grounded in academic research (including referenced Nature body-brain axis work) that aims to centrally control immune responses and restore immune homeostasis, with the stated potential to treat a wide spectrum of autoimmune and inflammatory diseases. The platform differentiates from existing immunomodulatory therapies by acting centrally on neural circuitry rather than on peripheral immune targets, addressing an unmet need where current treatments often have significant side effects or incomplete efficacy.

The company was founded in 2025 and launched publicly in October 2025 alongside a $101 million Series A financing — one of the largest Series A rounds in biotech history — led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Bill & Melinda Gates Foundation and Alexandria Venture Investments. Proceeds are allocated to establishing research laboratories in New York City, expanding the R&D team, and advancing preclinical programs. Nilo is led by CEO Kim Seth and CSO Laurens Kruidenier.

As a pre-revenue biotech, Nilo's future revenue model contemplates eventual drug commercialization through standard pharmaceutical distribution (one-time license economics in its current characterization), targeting two patient segments: autoimmune disease patients and inflammatory disease patients beyond core autoimmune indications. No commercial products, pricing, or licensing deals have been disclosed.

Short descriptiontext

NILO Therapeutics is a preclinical-stage New York City biotech developing a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to restore immune homeostasis in autoimmune and inflammatory disease patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunomodulatory therapeutics, autoimmune disease drugs, neural circuit therapeutics, inflammatory disease treatments, biopharmaceutical drug development
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immunomodulatory Therapeutics
No data
Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biotech company developing novel therapeutics targeting neural circuits. Revenue will be generated through commercializing drugs for autoimmune and inflammatory diseases once preclinical and clinical programs advance through development.

pharmiweb.com
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nilo Therapeutics is developing a novel class of medicines based on a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The platform is intended to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet medical need through a differentiated mechanism of action distinct from traditional peripheral immunomodulatory therapies. The company is currently in preclinical stage, establishing laboratories in New York City to advance its research programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Nilo Therapeutics is developing a new class of medicines based on a neural circuit immunomodulation platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The company is in preclinical stage with programs focused on treating autoimmune and inflammatory diseases. The platform represents a differentiated therapeutic approach compared to traditional immunomodulatory treatments.

Product and service1 record
1Neural Circuit Immunomodulation Platform
CategoryImmunomodulatory Therapeutics Platform
Description

A therapeutic platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis, intended to treat a wide spectrum of autoimmune and inflammatory diseases through a novel mechanism of action distinct from existing immunomodulatory therapies. The platform is in preclinical stage and is being developed by Nilo Therapeutics in New York City.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SetPoint Medical is a clinical-stage company developing bioelectronic vagus nerve stimulation to modulate systemic inflammation in autoimmune diseases (e.g., rheumatoid arthritis, Crohn's). It is the closest direct peer to Nilo, both targeting the neuroimmune axis to restore immune homeostasis in inflammatory disease.

TypeDirect peer
Description

Galvani Bioelectronics is a GSK/Verily joint venture developing miniaturized, implantable neuromodulation devices to treat chronic diseases including inflammatory and autoimmune conditions. It is a direct peer in neuroimmune modulation via electrical stimulation of disease-relevant neural circuits.

TypeDirect peer
Description

electroCore develops non-invasive vagus nerve stimulation (nVNS) therapies for inflammatory and neurological conditions, including rheumatoid arthritis and other autoimmune indications. It is a direct peer leveraging neural circuit engagement to treat immune-mediated disease.

TypeBroad incumbent
Description

AbbVie is a global biopharmaceutical leader in immunology (Humira, Skyrizi, Rinvoq) with deep commercial infrastructure in autoimmune and inflammatory disease. It is a broad incumbent whose therapeutic areas fully overlap Nilo's target indications, and an obvious strategic acquirer or partner for any validated neuroimmune asset.

TypeBroad incumbent
Description

Sanofi is a major immunology player (Dupixent franchise, growing IL-competitor pipeline) with active interest in differentiated mechanisms for inflammatory disease. As a broad incumbent in autoimmune and inflammatory therapeutics, Sanofi is a directly relevant comparator and potential strategic partner.

TypeBroad incumbent
Description

Roche operates one of the broadest immunology and neuroscience pipelines globally (Ocrevus, Actemra, Vabysmo) and is an obvious benchmark for CNS-immune platform value. As a broad incumbent, Roche is relevant for both competitive and BD comparison purposes.

TypeBroad incumbent
Description

Eli Lilly is a major immunology and neuroscience incumbent with Taltz, Olumiant, and an expanding neuroimmunology pipeline. As a broad incumbent with deep CNS and inflammation franchises, Lilly is a relevant comparator and potential strategic acquirer.

TypeBroad incumbent
Description

Pfizer has a sizeable immunology and inflammation portfolio (Cibinqo, Xeljanz, Litfulo) and an active BD presence in autoimmune disease. As a broad incumbent, it is a directly relevant peer for valuation and partnership benchmarking.

TypeEmerging player
Description

Karuna Therapeutics developed CNS-targeted therapies (xanomeline-trospium) for neuropsychiatric indications and was acquired by Bristol Myers Squibb for ~$14B. It is an emerging peer that demonstrates the premium valuation achievable by CNS-mechanism biotech companies that validate clinically, making it relevant for forward-look upside modeling on Nilo.

TypeEmerging player
Description

Sage Therapeutics pioneered CNS-targeted therapeutics (Zurzuvae, Zulresso) and executed a major collaboration with Biogen. As an emerging peer in CNS-mechanism drug development, Sage is relevant for partnership economics and platform valuation comparables.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NILO Therapeutics

Immunomodulatory Therapeuticsnilotx.com

NILO Therapeutics is a preclinical-stage New York City biotech developing a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to restore immune homeostasis in autoimmune and inflammatory disease patients.

What NILO Therapeutics does

NILO Therapeutics is a New York City-based, preclinical-stage biotechnology company developing a new class of medicines that modulate systemic inflammation by targeting master regulator brain-body circuits. Its core asset is the Neural Circuit Immunomodulation Platform, a therapeutic approach grounded in academic research (including referenced Nature body-brain axis work) that aims to centrally control immune responses and restore immune homeostasis, with the stated potential to treat a wide spectrum of autoimmune and inflammatory diseases. The platform differentiates from existing immunomodulatory therapies by acting centrally on neural circuitry rather than on peripheral immune targets, addressing an unmet need where current treatments often have significant side effects or incomplete efficacy.

The company was founded in 2025 and launched publicly in October 2025 alongside a $101 million Series A financing — one of the largest Series A rounds in biotech history — led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Bill & Melinda Gates Foundation and Alexandria Venture Investments. Proceeds are allocated to establishing research laboratories in New York City, expanding the R&D team, and advancing preclinical programs. Nilo is led by CEO Kim Seth and CSO Laurens Kruidenier.

As a pre-revenue biotech, Nilo's future revenue model contemplates eventual drug commercialization through standard pharmaceutical distribution (one-time license economics in its current characterization), targeting two patient segments: autoimmune disease patients and inflammatory disease patients beyond core autoimmune indications. No commercial products, pricing, or licensing deals have been disclosed.

NILO Therapeutics firmographics

Firmographics
Name
NILO Therapeutics
Legal name
Nilo Therapeutics
Website
https://nilotx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
NILO Therapeutics is a preclinical-stage New York City biotech developing a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to restore immune homeostasis in autoimmune and inflammatory disease patients.
Ownership category
akta.pro rank

NILO Therapeutics industry classification

Industry
Product category
Immunomodulatory Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Immunomodulatory therapeutics
  • Autoimmune disease drugs
  • Neural circuit therapeutics
  • Inflammatory disease treatments
  • Biopharmaceutical drug development

Where NILO Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NILO Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biotech company developing novel therapeutics targeting neural circuits. Revenue will be generated through commercializing drugs for autoimmune and inflammatory diseases once preclinical and clinical programs advance through development.

NILO Therapeutics product offering

Product offering

Core offering

Nilo Therapeutics is developing a novel class of medicines based on a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The platform is intended to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet medical need through a differentiated mechanism of action distinct from traditional peripheral immunomodulatory therapies. The company is currently in preclinical stage, establishing laboratories in New York City to advance its research programs.

Product overview

Nilo Therapeutics is developing a new class of medicines based on a neural circuit immunomodulation platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The company is in preclinical stage with programs focused on treating autoimmune and inflammatory diseases. The platform represents a differentiated therapeutic approach compared to traditional immunomodulatory treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Neural Circuit Immunomodulation Platform A therapeutic platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis, intended to treat a wide spectrum of autoimmune and inflammatory diseases through a novel mechanism of action distinct from existing immunomodulatory therapies. The platform is in preclinical stage and is being developed by Nilo Therapeutics in New York City.

Companies that use NILO Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

NILO Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

NILO Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

NILO Therapeutics competitors and assessment

Company assessment

Direct peers

  • SetPoint Medical: SetPoint Medical is a clinical-stage company developing bioelectronic vagus nerve stimulation to modulate systemic inflammation in autoimmune diseases (e.g., rheumatoid arthritis, Crohn's). It is the closest direct peer to Nilo, both targeting the neuroimmune axis to restore immune homeostasis in inflammatory disease.
  • Galvani Bioelectronics: Galvani Bioelectronics is a GSK/Verily joint venture developing miniaturized, implantable neuromodulation devices to treat chronic diseases including inflammatory and autoimmune conditions. It is a direct peer in neuroimmune modulation via electrical stimulation of disease-relevant neural circuits.
  • electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) therapies for inflammatory and neurological conditions, including rheumatoid arthritis and other autoimmune indications. It is a direct peer leveraging neural circuit engagement to treat immune-mediated disease.

Broad incumbents

  • AbbVie: AbbVie is a global biopharmaceutical leader in immunology (Humira, Skyrizi, Rinvoq) with deep commercial infrastructure in autoimmune and inflammatory disease. It is a broad incumbent whose therapeutic areas fully overlap Nilo's target indications, and an obvious strategic acquirer or partner for any validated neuroimmune asset.
  • Sanofi: Sanofi is a major immunology player (Dupixent franchise, growing IL-competitor pipeline) with active interest in differentiated mechanisms for inflammatory disease. As a broad incumbent in autoimmune and inflammatory therapeutics, Sanofi is a directly relevant comparator and potential strategic partner.
  • Roche: Roche operates one of the broadest immunology and neuroscience pipelines globally (Ocrevus, Actemra, Vabysmo) and is an obvious benchmark for CNS-immune platform value. As a broad incumbent, Roche is relevant for both competitive and BD comparison purposes.
  • Eli Lilly: Eli Lilly is a major immunology and neuroscience incumbent with Taltz, Olumiant, and an expanding neuroimmunology pipeline. As a broad incumbent with deep CNS and inflammation franchises, Lilly is a relevant comparator and potential strategic acquirer.
  • Pfizer: Pfizer has a sizeable immunology and inflammation portfolio (Cibinqo, Xeljanz, Litfulo) and an active BD presence in autoimmune disease. As a broad incumbent, it is a directly relevant peer for valuation and partnership benchmarking.

Emerging players

  • Karuna Therapeutics: Karuna Therapeutics developed CNS-targeted therapies (xanomeline-trospium) for neuropsychiatric indications and was acquired by Bristol Myers Squibb for ~$14B. It is an emerging peer that demonstrates the premium valuation achievable by CNS-mechanism biotech companies that validate clinically, making it relevant for forward-look upside modeling on Nilo.
  • Sage Therapeutics: Sage Therapeutics pioneered CNS-targeted therapeutics (Zurzuvae, Zulresso) and executed a major collaboration with Biogen. As an emerging peer in CNS-mechanism drug development, Sage is relevant for partnership economics and platform valuation comparables.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

NILO Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NILO Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

NILO Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NILO Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NILO Therapeutics

What does NILO Therapeutics do?

Nilo Therapeutics is developing a novel class of medicines based on a Neural Circuit Immunomodulation Platform that targets master regulator brain-body circuits to centrally control systemic inflammation and restore immune homeostasis. The platform is intended to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet medical need through a differentiated mechanism of action distinct from traditional peripheral immunomodulatory therapies. The company is currently in preclinical stage, establishing laboratories in New York City to advance its research programs.

Is NILO Therapeutics a public or private company?

NILO Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was NILO Therapeutics founded?

NILO Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is NILO Therapeutics based?

NILO Therapeutics is headquartered in New York, United States, in the North America region.

How does NILO Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are NILO Therapeutics's main competitors?

Direct peers on record are SetPoint Medical, Galvani Bioelectronics and electroCore. Broad incumbents are AbbVie, Sanofi, Roche, Eli Lilly and Pfizer. Emerging players are Karuna Therapeutics and Sage Therapeutics.

Does NILO Therapeutics have an API?

No public API is recorded for NILO Therapeutics.

What industry is NILO Therapeutics in?

NILO Therapeutics's product category is Immunomodulatory Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyNew AI research reshapes neuroprotective drug discovery fundingBCC Research published a Pulse report titled "AI Impact on Neuroprotective Agents" forecasting the North American neuroprotective agents market to grow at approximately 4.5% CAGR through 2030, with hundreds of millions flowing into AI-driven neuroscience startups. The research documents intensifying pharma-tech collaborations including Eli Lilly's partnership with NVIDIA to build an AI supercomputer, a $200 million joint venture between MeiraGTx and Hologen, and Biogen's work with TheraPanacea, while identifying recent venture raises by Nilo Therapeutics, Verge Genomics, Chai Discovery, NRG Therapeutics, BEXORG, and Illimis Therapeutics. The report frames these developments as creating new investor opportunities and describes AI deployment across the drug discovery value chain from target identification to precision dosing.VC News DailyNilo Therapeutics Launches With $101M Series A FinancingNilo Therapeutics, a biotechnology company developing neural circuit-based therapies to restore immune homeostasis, launched with a $101 million Series A financing round led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. The company simultaneously announced the appointment of Kim Seth, Ph.D. as Chief Executive Officer and Board director. The substantial Series A funding will support the company's research and development activities in its inaugural year.FinSMEsNilo Therapeutics Raises $101M in Series A FinancingNilo Therapeutics raised $101M in Series A financing led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. The company, founded by Charles Zuker, Ruslan Medzhitov, and Steve Liberles, will use the funds to establish labs in New York City and advance preclinical programs.PharmiWeb.comNilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive OfficerNilo Therapeutics, a biotechnology company developing medicines that harness neural circuits to restore immune homeostasis, launched with a $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. The company appointed Kim Seth as Chief Executive Officer and will use the funding to establish laboratories in New York City, grow its R&D team, and advance preclinical programs targeting autoimmune and inflammatory diseases. The therapeutic approach is based on scientific discoveries from Columbia University identifying vagal neurons that regulate systemic immune activation and inflammation.BusinessGhanaNilo Therapeutics launches with $101 million Series A financing to advance a new class of medicinesNilo Therapeutics, a biotechnology company developing medicines that harness neural circuits to restore immune homeostasis, launched with a $101 million Series A financing co-led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. Founded by scientists from Columbia, Yale, and Harvard universities, the company is pioneering a novel approach to immunomodulation that targets central brain-body circuits to treat autoimmune and inflammatory diseases, moving beyond conventional immunosuppression. The funding will support the establishment of laboratories in New York City and advance the company's preclinical programs.GlobeNewswireNilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive OfficerNilo Therapeutics launched with a $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital, and appointed Kim Seth as CEO. The company develops drugs targeting neural circuits to restore immune homeostasis in autoimmune and inflammatory diseases.GlobeNewswireNilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive OfficerNilo Therapeutics launched with a $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. The funding will support establishment of laboratories in New York City, growth of the R&D team, and advancement of preclinical programs developing drugs that harness neural circuits to restore immune homeostasis in autoimmune and inflammatory diseases. Kim Seth, with over 25 years of biopharma experience including roles at Repare Therapeutics and Goldman Sachs, was appointed CEO to lead the company into its next stage of growth.SecSEC FORM DNILO Therapeutics, Inc. filed a Form D with the SEC to announce an exempt securities offering under Rule 506(b). The company has raised $9.6 million out of a total target of $101 million from three investors as of July 2024.